Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04093596 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
A Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by Allogene Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 11
- Study locations
NCT04093596 is a Phase 1 study of Relapsed/Refractory Multiple Myeloma that is active but no longer recruiting, run by Allogene Therapeutics. The registered enrollment target is 132 participants, below the 165-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (20% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT04093596, a Phase 1 study of Relapsed/Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Allogene Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide, or ALLO-647 alone.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Nirogacestat
- BIOLOGICAL ALLO-647
- GENETIC ALLO-715
Study Locations (11)
California
- City of Hope - Duarte
- Stanford Cancer Institute - Palo Alto
Texas
- St. David's South Austin Medical Center - Austin
- Texas Transplant Institute - San Antonio
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Colorado
- Sarah Cannon/Colorado Blood Cancer Institute - Denver
Minnesota
- Mayo Clinic - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04093596
The ClinicalTrials.gov registry entry for NCT04093596 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (20% lower). The listed sponsor is Allogene Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04093596 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT04093596 about?
NCT04093596 is a clinical study titled "Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)". The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide,...
What is the current status of trial NCT04093596?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2019-09-23. Estimated completion is 2027-09.
What conditions does trial NCT04093596 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT04093596?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Nirogacestat (DRUG), ALLO-647 (BIOLOGICAL), ALLO-715 (GENETIC).
Who is sponsoring clinical trial NCT04093596?
This trial is sponsored by Allogene Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04093596 being conducted?
This trial has 11 study locations across Arizona, California, Colorado, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.